Rifampin (oral): Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) mNo edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}} | {{XXXXX}} | ||
{{CMG}}; {{AE}} {{chetan}} | |||
==Overview== | ==Overview== | ||
==Category== | ==Category== | ||
Antimycobacterial | |||
==US Brand Names== | ==US Brand Names== | ||
RIFADIN<sup>®</sup> | |||
==FDA Package Insert== | ==FDA Package Insert== | ||
'''[[XXXXX description|Description]]''' | |||
''' | |||
'''| [[XXXXX clinical pharmacology|Clinical Pharmacology]]''' | '''| [[XXXXX clinical pharmacology|Clinical Pharmacology]]''' | ||
'''| [[XXXXX microbiology|Microbiology]]''' | '''| [[XXXXX microbiology|Microbiology]]''' | ||
| Line 23: | Line 17: | ||
'''| [[XXXXX warnings and precautions|Warnings and Precautions]]''' | '''| [[XXXXX warnings and precautions|Warnings and Precautions]]''' | ||
'''| [[XXXXX adverse reactions|Adverse Reactions]]''' | '''| [[XXXXX adverse reactions|Adverse Reactions]]''' | ||
'''| [[XXXXX overdosage|Overdosage]]''' | '''| [[XXXXX overdosage|Overdosage]]''' | ||
'''| [[XXXXX clinical studies|Clinical Studies]]''' | '''| [[XXXXX clinical studies|Clinical Studies]]''' | ||
'''| [[XXXXX dosage and administration|Dosage and Administration]]''' | '''| [[XXXXX dosage and administration|Dosage and Administration]]''' | ||
'''| [[XXXXX compatibility reconstitution and stability|Compatibility, Reconstitution, and Stability]]''' | |||
'''| [[XXXXX directions for use|Directions For Use]]''' | |||
'''| [[XXXXX how supplied|How Supplied]]''' | '''| [[XXXXX how supplied|How Supplied]]''' | ||
'''| [[XXXXX labels and packages|Labels and Packages]]''' | '''| [[XXXXX labels and packages|Labels and Packages]]''' | ||
== | ==Mechanisms of Action== | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Antibiotics]] | [[Category:Antibiotics]] | ||
[[Category:Wikinfect]] | [[Category:Wikinfect]] | ||
Revision as of 18:17, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Overview
Category
Antimycobacterial
US Brand Names
RIFADIN®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Labels and Packages